Insider · CIK 0001303782
Jonathan C Javitt
Files at NRXP (NRX Pharmaceuticals, Inc.). First filing Dec 18, 2024, latest Dec 18, 2024.
In brief
Jonathan C Javitt files SEC Form 4 as chair, director and 10% owner at NRXP (NRX Pharmaceuticals, Inc.). Since Dec 18, 2024, Jonathan C Javitt has reported 1 open-market buy worth $47k and 0 open-market sells worth $0, the latest filed on Dec 18, 2024.
A track record needs three past buys with six months of prices behind them; Jonathan C Javitt has 0, so none is measured yet.
The newest scored trade: bought $47k of NRXP on Dec 17, 2024, filed Dec 18, 2024, scored 36 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NRXP: NRX Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | NRXPbuy NRX Pharmaceuticals, Inc. | $47k 40,000 shares | +90% | - |
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 9, 2025 | NRXP NRX Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Sep 10, 2025 |
| Dec 17, 2024 | NRXP NRX Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +40,000 | $1.17 | $47k | 84,634 | Dec 18, 2024 |
Questions about Jonathan C Javitt
Answered from the filings on this page, as of the latest one.
Is Jonathan C Javitt buying or selling?
Not in the last 12 months. Jonathan C Javitt's latest open-market trade on SEC Form 4 was bought $47k of NRXP on Dec 17, 2024.
How did Jonathan C Javitt's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jonathan C Javitt has 0.
Where does Jonathan C Javitt file Form 4?
Jonathan C Javitt has filed Form 4 at NRXP (NRX Pharmaceuticals, Inc.) as Chairman and Chief Scientist. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.